Edwards Lifesciences Corporation (EW)
NYSE: EWHealth CareIndustrial SpecialtiesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EW stock chart
Technical analysisKey statistics
All statistics- Market cap
- $58.56B
- P/E (TTM)
- 59.22
- Forward P/E
- 30.08
- EPS (TTM)
- $1.72
- Dividend yield
- None
- 52-week range
- 74.66 – 108.00
- Day range
- 101.66 – 104.92
- Volume / Avg
- 3.62M / 3.92M
- Beta
- —
- Shares outstanding
- 575.00M
52-week range
EW stock today
Shares of Edwards Lifesciences (EW) finished lower on Nov 20 at $101.85, a drop of 1.95% or $2.03 per share, versus the S&P 500's 3.70% decline. At this level, EW sits near the top of its 52-week range of $74.66 to $108.00: 5.7% below the high, set on Nov 16, 2026 and 36.4% above the low. EW is up 19.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 19.6%.
At 59.2x trailing earnings, Edwards Lifesciences trades above the peer-group median of 22.2x. Its forward P/E of 30.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Edwards Lifesciences
Company profileEdwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
- Sector
- Health Care
- Industry
- Industrial Specialties
- CEO
- Mr. Bernard J. Zovighian
- Headquarters
- Irvine, CA
- Employees
- 16,000
- Website
- edwards.com
Financial highlights
Full financialsIn fiscal 2025, Edwards Lifesciences generated $6.07 billion in revenue, up 11.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $1.07 billion (-74.3% year over year), for a net margin of 17.7% versus a median of 28.7% in the prior 5 years. Gross margin was 78.0% (down from 79.5%) and operating margin 20.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Growth | +11.55% | +8.57% | +12.23% | -14.69% | +19.29% |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| EPS (diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
Analyst forecast
ForecastConsensus (30 analysts)
buy
Avg. price target
$113.68+11.62%
- Strong buy 5
- Buy 20
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $0.67 vs $0.73
- Surprise
- -8.22%
EW news
All EW news- Edwards Lifesciences Corporation Enters into $750 million Amended and Restated Credit AgreementNasdaq
- BSX's Weak Solvency and Cash Conversion Raise Financing RiskNasdaqBSX, MDT, EW
- Edwards Lifesciences: Momentum Returns, But Valuation Warrants CautionSeeking Alpha
- Should You Book Profits or Hold BSX Stock Post-Q3 Earnings?NasdaqBSX, BDX, EW
- Top Stock Reports for Visa, ExxonMobil & PfizerNasdaqBX, V, XOM, PFE
- Boston Scientific Bets on WATCHMAN Growth Despite Market SlowdownNasdaqBSX, ABT, EW
- Edwards Lifesciences Q3 Earnings Call HighlightsNasdaq
- Interactive Brokers Group Moves Up In Analyst Rankings, Passing Edwards LifesciencesNasdaqIBKR, EW
Edwards Lifesciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STESTERIS plc (Ireland) | 255.76 | +0.39% | $24.84B | vs EW |
| ZBHZimmer Biomet Holdings Inc. | 101.10 | -0.36% | $19.13B | vs EW |
| MASMasco Corporation | 82.60 | -0.23% | $15.92B | vs EW |
| SNNSmith & Nephew SNATS Inc. | 29.83 | 0.00% | $12.47B | vs EW |
| ALGNAlign Technology Inc. | 155.17 | -2.82% | $10.94B | vs EW |
| AITApplied Industrial Technologies Inc. | 274.99 | -4.65% | $10.04B | vs EW |
| POOLPool Corporation | 208.23 | -0.70% | $7.44B | vs EW |
| MSAMSA Safety Incorporated | 170.03 | -3.52% | $6.55B | vs EW |
Indexes, lists and sector
Index membership
Edwards Lifesciences stock FAQ
What is Edwards Lifesciences's stock price today?
EW last traded at $101.85 as of Nov 20, 4:00 PM EST, down 1.95% on the day. Prices are delayed at least 15 minutes.
Does Edwards Lifesciences pay a dividend?
No. Edwards Lifesciences does not currently pay a regular cash dividend.
What is EW's P/E ratio?
EW trades at a trailing P/E ratio of 59.22 and a forward P/E of 30.08, compared with a median of 22.2 for its closest peers.
Is Edwards Lifesciences in the S&P 500?
Yes. Edwards Lifesciences (EW) is a constituent of the S&P 500 index.
Who is Edwards Lifesciences's CEO?
Mr. Bernard J. Zovighian is the chief executive officer of Edwards Lifesciences Corporation, which has about 16,000 employees.
Has EW ever split its stock?
Yes. The most recent EW stock split was a 3-for-1 split on Jun 1, 2020, one of 3 splits on record.
What is the EW 52-week high?
The 52-week high for EW is $108.00 and the 52-week low is $74.66. The stock is currently 5.7% below its high.